CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4.
37th Annual Piper Sandler Healthcare Conference
Date: Tuesday, December 2, 2025
Format: Fireside chat and 1×1 meetings
Time: 4:00 p.m. – 4:25 p.m. ET
Location: New York, NY
The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
Toronto, Ontario--(Newsfile Corp. - December 5, 2025) - Predictmedix AI Inc. (CSE: PMED) (OTC Pink:…
BOISE, Idaho, Dec. 5, 2025 /PRNewswire/ -- Techficient, a leading innovator in Insurtech solutions, announces the…
Company brings its Scientific Activation™ mission to life at ASH Annual Meeting following November rebrand RESTON,…
MOHEGAN LAKE, N.Y., Dec. 5, 2025 /PRNewswire/ -- Shrub Oak International School today announced enhanced…
National poll reveals 27% of workers prefer dental work over office celebrations as workplace disconnection…
Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA…